Buy Zofran from Discount Pharmacy
We are a leading Canadian mail-order pharmacy service focusing on both on prescription cost-containment and patient safety. We only work with a small network of trusted and reputable international pharmacies and fulfillment centers, giving you access to authentic medications at low prices every day. All medications are shipped directly to you from our affiliated licensed international and Canadian pharmacies and fulfillment centers. Our staff are knowledgeable and efficient to ensure that your shopping experience is hassle free. Save on prescription drugs like Zofran as well as other prescription drugs like Avodart, Avapro, Evista, Fosamax, Lunesta, Norvasc, Protonix, Singulair, Valtrex, Zoloft.
10 Great Reasons to Choose Our Service!
Your Zofran are shipped in sealed drug manufacturer's containers from the licensed pharmacy.
Your prescription drugs are mailed directly to your home from our licensed Canadian pharmacy in Canada.
Canadian Prescription drugs are non-taxable when you purchase them from Canada.
Live and friendly customer service staff available 5 days a week ready to help your questions or assist you in ordering.
The Canadian dollar performs weaker than the US dollar. This gives American more spending power when buying from Canada.
All of your drug prescriptions are reviewed by a Canadian physician and filled by a Canadian licensed pharmacists from our Canadian Pharmacy.
Prompt and efficient service from our Canadian pharmacy means your prescription drugs will be delivered in 2-3 weeks from the time your prescription order is received.
All Canadian prescription drugs have been approved for sale by Health Canada, the Canadian FDA equivalent.
Many towns, cities and states are encouraging their citizens to consider buying their prescription medications from International pharmacies.
Why Are Cancer Drugs So Expensive?
The high cost of cancer drugs is related to a number of factors. It is very very expensive to move findings from bench to bedside and to perform all the regulatory studies (from phase 1, 2, and 3 clinical trials) to gain approval. Second, even when the monopoly is broken with the arrival of 'new and improved' versions of an approved drug, the older drug (and by now generic) tends to be viewed as substandard treatment, thereby perpetuating the situation. Third, the very nature of cancer, and the seriousness of the diagnosis, plays a role in that patients and physicians are often willing to pay the high price of treatment even for marginal improvements in outcome. Finally, because most cancers are incurable, patients are treated with each approved agent creating a virtual monopoly because the use of one drug does not automatically mean that the others are no longer needed.